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Heme oxygenase-1 (HO-1) induction by hemin, the
active ingredient of an FDA-approved biologic for the
treatment of acute porphyries, has been previously shown
in our laboratory to effectively inhibit HIV-1 replication.
The present study was undertaken to expand these obser-
vations to examine the inhibitory role of HO-1 in the
pathogenesis of XMRV infection. Hemin-induced HO-1
activation in LNCaP, a prostate cancer cell line suscepti-
ble to XMRV infection, markedly down-modulated the
cell surface expression of XMRV receptor Xpr1, and sig-
nificantly inhibited their ability to support productive
virus replication. Hemin treatment of XMRV-integrated
prostate carcinoma cells 22Rv1 was relatively less effec-
tive in suppressing the rapidly replicating XMRV in these
aggressive malignant cells; yet it efficiently inhibited
XMRV infection of LNCaP cells by about 80% when cul-
tured for three days in the virus-containing 50% condi-
tioned media from 22Rv1 cells. Additionally, HO-1
induction retarded the growth of uninfected LNCaP cells,
XMRV-infected LNCaP cells and 22Rv1 cells, and signifi-
cantly reduced their invasiveness to the reconstituted
basement membrane matrix Matrigel, consistent with the
lower levels of basement membrane degrading enzyme
matrix metalloproteinase-9. These findings indicate a
pivotal role of HO-1 as a host cell defense mechanism in
prostate carcinogenesis in vitro, and may offer HO-1
induction as a potentially novel therapeutic strategy to
control the pathogenesis of XMRV infection.
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